CARNA BIOSCIENCES, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 414 JPY | -2.82% |
|
-7.38% | -20.69% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 1.39B 8.85M | Sales 2023 | 1.62B 10.38M | Capitalization | 8.95B 57.17M |
|---|---|---|---|---|---|
| Net income 2022 | -1.35B -8.62M | Net income 2023 | -1.15B -7.36M | EV / Sales 2022 | 3.11 x |
| Net cash position 2022 | 3.08B 19.68M | Net cash position 2023 | 2.71B 17.29M | EV / Sales 2023 | 3.84 x |
| P/E ratio 2022 |
-5.25
x | P/E ratio 2023 |
-7.61
x | Employees | 67 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 89.76% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.82% | ||
| 1 week | -7.38% | ||
| Current month | -3.94% | ||
| 1 month | -10.97% | ||
| 3 months | -6.97% | ||
| 6 months | -50.83% | ||
| Current year | -20.69% |
1 week
412.00
462.00
1 month
404.00470.00
Current year
404.00543.00
1 year
404.001 060.00
3 years
404.001 736.00
5 years
404.003 300.00
10 years
404.006 030.00
| Managers | Title | Age | Since |
|---|---|---|---|
| President | 75 | 03-04-09 | |
Emi Yamamoto
ADM | Chief Administrative Officer | 53 | 03-12-31 |
Masaaki Sawa
CTO | Chief Tech/Sci/R&D Officer | 53 | 06-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Teruo Takayanagi
BRD | Director/Board Member | 77 | 15-02-28 |
Tsuguo Ogasawara
BRD | Director/Board Member | 84 | 05-02-28 |
| President | 75 | 03-04-09 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-20 | 414 | -2.82% | 84 600 |
| 24-05-20 | 426 | -2.29% | 144,100 |
| 24-05-17 | 436 | +0.23% | 119,000 |
| 24-05-16 | 435 | -2.47% | 109,000 |
| 24-05-15 | 446 | -0.22% | 130,100 |
Delayed Quote Japan Exchange, May 20, 2024 at 10:30 pm EDT
More quotes
Carna Biosciences, Inc. is a Japan-based company mainly engaged in the drug development support business and the drug development business. The Company operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.
Calendar
2024-08-06
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -20.69% | 48.11M | |
| +41.79% | 50.93B | |
| -0.56% | 42.12B | |
| +49.62% | 42.05B | |
| -7.20% | 29.18B | |
| +12.59% | 26.02B | |
| -21.51% | 18.9B | |
| +6.92% | 13.21B | |
| +24.91% | 12.17B | |
| +29.60% | 12.16B |
- Stock Market
- Equities
- 4572 Stock
